H1N1 (swine flu) & the R&D-based Pharmaceutical Industry
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
On 25 September 2026, at the conclusion of the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response, IFPMA issued a statement, urging governments to accelerate practical commitments that strengthen preparedness for future health crises.
Read moreOn 25 September 2026 in New York City, IFPMA submitted a statement at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response. Panel 1: Multilateral action for coordinated pandemic prevention, preparedness, and response, including sharing of best practices and lessons learned so far The COVID-19 pandemic and outbreaks including Ebola have reinforced a simple...
Read moreThe global pharmaceutical industry is urging governments to seize the opportunity of the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response (PPPR) to accelerate practical commitments that strengthen preparedness for future health crises.
Read more